[Treatment of primary hyperlipoproteinemia type IIb and IV. Comparison of the lipid lowering effect of phenformin, clofibrate, and a combination of both (author's transl)].
22 outpatients with primary hyperlipoproteinemia type IIb and IV were treated in periods of eight weeks as follows: placebo; 0,15 g phenformin/day; 0,15 g phenformin + 1,5 g clofibrate/day; 1,5 g clofibrate/day; placebo. Compared to the first placeboperiode the serumtriglycerides were significantly lowered by phenformin (about 26%), by the combined treatment with phenformin + clofibrate (60%) and by clofibrate (51%) after eight weeks of treatment. The serumcholesterol was significantly lowered by phenformin (10%) and by the combined treatment with phenformin and clofibrate (14%), but not significantly by clofibrate (8%). After eight weeks of treatment with phenformin alone or in combination with clofibrate the body weight decreased significantly (1,9% or 1,4%). These changes in body weight were not related to changes in blood lipids. In conclusion, the combined treatment with 0,15 g clofibrate/day was more effective in lowering increased serum lipids than the treatment with phenformin or clofibrate alone.
D000328:Adult; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010629:Phenformin / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D014280:Triglycerides / Q000097:blood
D010919:Placebos; D014280:Triglycerides; D002784:Cholesterol; D010629:Phenformin; D002994:Clofibrate
Therapie primärer Hyperlipoproteinämien Typ IIb und IV. Vergleich der serumlipidsenkenden Wirkung von Phenformin, Clofibrat und der Kombination von Phenformin mit Clofibrat.